Blocking the FKBP12 induced dendrimeric burst in aberrant aggregation of &#945;-synuclein by using the ElteN378 synthetic inhibitor by Caminati, Gabriella et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ienz20
Journal of Enzyme Inhibition and Medicinal Chemistry
ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: https://www.tandfonline.com/loi/ienz20
Blocking the FKBP12 induced dendrimeric burst in
aberrant aggregation of α-synuclein by using the
ElteN378 synthetic inhibitor
Gabriella Caminati, Maria Raffaella Martina, Stefano Menichetti & Piero
Procacci
To cite this article: Gabriella Caminati, Maria Raffaella Martina, Stefano Menichetti & Piero
Procacci (2019) Blocking the FKBP12 induced dendrimeric burst in aberrant aggregation of α-
synuclein by using the ElteN378 synthetic inhibitor, Journal of Enzyme Inhibition and Medicinal
Chemistry, 34:1, 1711-1715
To link to this article:  https://doi.org/10.1080/14756366.2019.1667342
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 24 Sep 2019.
Submit your article to this journal 
View related articles 
View Crossmark data
SHORT COMMUNICATION
Blocking the FKBP12 induced dendrimeric burst in aberrant aggregation of
a-synuclein by using the ElteN378 synthetic inhibitor
Gabriella Caminatia,b, Maria Raffaella Martinaa,b, Stefano Menichettib and Piero Procaccib
aDepartment of Chemistry “Ugo Schiff”, University of Florence, Sesto Fiorentino, Italy; bCenter for Colloid and Surface Science (CSGI), University
of Florence, Sesto Fiorentino, Italy
ABSTRACT
a-Synuclein (a-syn), a disordered cytoplasmatic protein, plays a fundamental role in the pathogenesis of
Parkinson’s disease (PD). Here, we have shown, using photophysical measurements, that addition of
FKBP12 to a-syn solutions, dramatically accelerates protein aggregation, leading to an explosion of den-
dritic structures revealed by fluorescence and phase-contrast microscopy. We have further demonstrated
that this aberrant a-syn aggregation can be blocked using a recently discovered non-immunosuppressive
synthetic inhibitor of FKBP12, ElteN378. The role of FKBP12 and of ElteN378 in the a-syn aggregation
mechanism has been elucidated using molecular dynamics simulations based on an effective coarse-
grained model. The reported data not only reveal a new potent synthetic drug as a candidate for early
stage treatment of a-syn dependent neurodegenerations but also pave the way to a deeper understand-
ing of the mechanism of action of FKBP12 on a-syn oligomeric aggregation, a topic which is still
controversial.
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Introduction
The plastic a-syn protein is a key player in the pathogenesis of
Parkinson’s disease (PD)1–3. In pathological conditions, this protein
is present in the brain cells in fibrillar, aggregated forms called
Lewy bodies. Members of the FK506-binding protein (FKBP) family
were recently shown to be implicated in neurological disorders
and structure formation1,3,4. The involvement of FKBP12 in the
pathogenesis of a-syn-dependent neurodegeneration has been
repeatedly shown in post-mortem studies on the brain of patients
with neurodegenerative diseases1,5,6. Recent investigations
revealed an unbalance of the endogenous FKBP12 concentration
in the very early stages of PD4, as well as the presence of FKBP12
in Lewy bodies6. Beeklandt and coworkers7 proposed that proteins
of the FKBP family, and notably FKBP12, induce a faster aggrega-
tion of amyloid a-syn, by binding a-syn via the prolyl peptidyl
isomerase domain8 to one of the proline in the hydrophilic C-ter-
minus of the monomer9. Despite the cited mounting evidence
about a possible role for FKBP12 in synucleopathies and neuro-
logical disorders through the enhancement of a-syn aggregation,
the mechanism of such enhancement has not been unraveled yet.
In Figure 1, we show a ribbon representation of a-syn mono-
mer along with the FKBP12 protein. The a-syn monomer primary
structure comprises three distinct segments. The C terminus
(92–140) is a polar coil region bearing a strong negative charge
(15e) and hosting all five prolines in a-syn. The equally polar
1–40N a-helical10 terminus has a mixture of negatively and posi-
tively charged residues with a slight prevalence of the latter
(þ3e). The central NAC domain, including amino-acids 40 to 92, is
characterised by a sequence of mostly hydrophobic residues and
is involved in b-sheet formation11. Several studies have shown
that a-syn fibrils are characterised by a b-rich hydrophobic solvent
protected core12–15 with external hydrophilic filaments due to the
C and N termini.
Using a combined approach of experimental measurements
and molecular dynamics simulations, in this contribution we aim
at elucidating the role of FKBP12 in a-syn aggregation kinetics
and aggregate morphology suggesting at the same time a pos-
sible therapeutic agent, the synthetic ElteN378 FKBP12 inhibitor16,
in PD neuropathies. ElteN378 is a low atomic weight FKBP12 lig-
and with affinity comparable to that of the natural binder FK506.
This ligand is affordable from commercially available precursors
and, as shown in Supplementary Figure S1 in Supporting
Information, has been designed to optimally expose the two con-
tiguous carbonyl oxygen atoms in the proline-mimetic chain for
H-bond-driven FKBP12 docking16.
Aggregation of a-syn was studied in vitro following the change
in the photophysical behaviour of the fluorescent probe ThT in
three different systems: a-syn, a-syn/FKBP12 1:1 and a-syn/FKBP12
1:1 inhibited by ElteN378. Imaging of mature aggregates of the
previous systems was obtained with fluorescence and phase-
contrast microscopy. The collected experimental evidence on
aggregation kinetics and morphology was interpreted using
extensive MD simulations based on a coarse-grained model (CG)
for a-syn and a-syn-bound FKBP12 monomers with inter- and
intra-molecular interactions driven by a potential mean force
effectively accounting for the amphiphilic nature of the a-syn
monomer. The results showed striking similarities between the
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structures obtained from the CG simulations and the experimen-
tally observed morphology of the aggregates suggesting that the
mechanism and fate of the aggregation process can be dramatic-
ally modified by altering the balance between hydrophilic and
hydrophobic forces.
Aggregation kinetics
Unseeded samples were incubated at 37 C in glass vials under
gentle constant stirring17. We used 1 mM concentration for both
a-syn and FKBP12 in Tris buffer. The physiological cytosolic con-
centration of a-syn is brain cells was reported to be18 in the low
micromolar range and is probably even below this level19. On
the other hand, FKBP12 is especially abundant in brain20 with
physiological concentrations reaching 3 mM, according to
recent studies21.
Aliquots of the incubated solutions were withdrawn and char-
acterised at different time intervals for 20weeks. ThT was added
only before each measurement to avoid probe-induced artifacts
on aggregation. At the working ThT concentration used in this
work (3 mM), the probe is present in solution exclusively as mono-
mer and the corresponding emission spectrum shows a single
weak emission band centred at 445 nm (Supplementary Figure
S4a) upon excitation at 350 nm, as commonly found22,23 for ThT
monomer in protic solvents. Control experiments exclude ThT
interaction with native a-syn or with the globular FKBP12, in
agreement with literature reports24. Further details on the experi-
mental procedures are reported in Supporting Information.
When ThT was added to a-syn solutions we observed a signifi-
cant change in the position and the intensity of the excitation
and emission bands: in Figure 2, we report the ThT fluorescence
intensity at kem ¼480 nm with kexc ¼410 nm as a function of time
for all examined systems. For free a-syn, in the absence of any
added seed, ThT emission intensity changes with time following
the well-known sigmoidal curve23,25 although the lag phase is
contracted in this time scale. The curve is consistent with a nucle-
ation-dependent elongation model of fibril formation26,27. After
18 days, aggregation proceeds through elongation of the protofi-
brils without further change in ThT emission. In the equimolar
a-syn-FKBP12 system, fluorescence emission increases at a faster
rate reaching larger intensity values at a much earlier stage
(10 days), before decreasing to a plateau value.
Addition of 200 nM ElteN378 inhibitor in the FKBP12-a-syn sys-
tem results in a similar kinetic profile but with a reduction of the
aggregated phase, followed, once more, by a decrease in ThT sig-
nal. While rarely reported in conventional aggregation studies28,
the decrease in ThT fluorescence in aged a-syn containing solu-
tions, consistently detected in all analysed independent samples
can be explained by a combination of chemical-physical effects
that include (i) redistribution of the ThT probe in other sites of
the growing oligomers characterised by a shift of the maximum of
ThT emission band, (ii) formation of mature aggregates with differ-
ent morphology and exposed b-sheet content (interconverting
structures), and (iii) partial loss of emission intensity due to depos-
ition of fibrillar tangles. The stabilisation of the ThT fluorescence
signal in long term measurements allows for the exclusion of pro-
gressive sedimentation of large aggregates.
In order to elucidate the observed aggregation kinetics, we
have done extensive MD simulations based on an elementary CG
model for a-syn and a-syn-bound FKBP12 using the program
ORAC29,30. Computational details on the CG approach are pro-
vided in Supporting Information. Briefly, we adopt a 15 beads CG
representation of the monomeric a-syn chain, made up of three
distinct parts of five beads length each: a central hydrophobic
part representing the NAC domain and two terminal hydrophilic
parts. The five beads approach is based on a recent model for the
a-syn mature fibrils based on a five strands monomer11,31,32. We
use a solvent-free model with renormalised bead-bead non-
bonded interactions so as to mimic, in a water environment, the
aggregation of hydrophobic moieties and solubilisation of the
hydrophilic groups. We further assume that, when proline-bound
to the C terminus of a-syn, the globular protein FKBP12 exposes
an unsaturated b-strand acting as a seed for the binding of the
b-sheet forming NAC domain, as illustrated in Figure 1.
The FKBP12 addition at the onset of a-syn aggregation is
hence modelled by simply replacing one of the terminal hydro-
philic beads with a hydrophobic one in a fraction, say /, of a-syn
monomers computed according to the nominal concentration of
the species and to the equilibrium dissociation constant for the
FKBP12-a-syn complex estimated to be in the micromolar range
(see Supporting Information). The effect of the tight-binding
ElteN378 inhibitor in the a-syn-FKBP12 solution is simply that of
reducing the FKBP12-effective concentration in a strictly dose-
dependent manner. In Figure 3, we show the calculated CG kinet-
ics for the pure a-syn and for samples with different fractions / of
FKBP12-modified a-syn monomers. Inspection of Figure 3 shows
that the kinetics is accelerated with increasing fraction of FKBP12-
modified a-syn molecules. Correspondingly, the final stationary of
value of the average number nmol grows with the fraction of
FKBP12-bound a-syn monomers, ending up to only few supra-
molecular macro-aggregates for />0.5. In the inset, we report the
final value of nmol as a function of / evidencing the non-linear
effect of FKBP12 addition. Up to /¼ 0:3, the aggregation kinetics
resembles that observed in the sample of pure a-syn. Above the
threshold fraction of /> 0.3, the aggregation kinetics undergoes
an abrupt regime cross-over, exhibiting a much faster growth
Aggregation morphology
Aliquots of the mature incubated solutions were imaged by
means of fluorescence and phase-contrast microscopy. Typical
fluorescence images, consistently observed in all independent
samples, are reported in Figure 4 while typical phase contrast
results are shown in Supplementary Figure S2. As shown in the
upper panel left image of Figure 4, images of a-syn at very long
aggregation times show the presence of a high concentration of
linear structures as found also by other authors14.
Figure 1. a-syn and FKBP12 structures. Red and blue balls on a-SYN indicate
negatively and positively charged residues, respectively. Proline is indicated in
yellow colour.
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The linear morphology of the fibril in a-syn aggregation has
been rationalised32,33 in terms of an in-register parallel b-sheet
structure with systematic stacking of the hydrophobic NAC
domains of the monomers along the fibril axis. The central upper
panel of Figure 4 shows images of samples taken from an equi-
molar solution of FKBP12-a-syn. The observed aggregation pattern
is dramatically different, exhibiting an impressive dendritic explo-
sion of highly branched structures. Remarkably, such quasi-fractal
growth is strongly reduced when ElteN378 is present in the a-syn/
FKBP12 system: the number of branching nodes is drastically
scaled down resulting in much smaller and less abundant
aggregates with a cross-like morphology. The rational for the
observed behaviour lies in the strong binding affinity of ElteN378
for FKBP12, previously reported by us16. The presence of the
tightly bound ElteN378 in the FKBP12 substrate pocket prevents
the possibility of FKBP12 to interact with the proline-rich C ter-
minus of a-syn. This translates in a reduction of the concentration
of “active” FKBP12 seeds for explosive branching of
a-syn aggregates.
The lower panel of Figure 4 refers to the end states of the CG
simulations for different fraction of FKBP12-doped a-syn. In strik-
ing correspondence with the experimental observations, the
Figure 2. Fluorescence emission intensity at k¼ 480 nm for a-syn (green circles), a-syn/FKBP12 (black squares) and a-syn/FKBP12/ElteN378 (blue triangles) systems.
For each system, the reported error bars have been computed by analysing the ThT fluorescence intensity measured in three independent samples (see Supporting
Information for further details).
Figure 3. Aggregation kinetics measured by the average number of monomers composing the aggregates for various fractions / (see text) of FKBP12-bound a-syn.
The total number of the 15-beads a-syn monomers is in all case equal to 512. For each fraction, the errors have been evaluated by averaging the data over three
independent simulations. In the inset, we report the average number of monomers composing the aggregates in the final configuration.
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sample containing only a-syn (/¼0) spontaneously aggregates in
linear fibrils exposing the hydrophilic filaments towards the solv-
ent, roughly perpendicularly to the fibril axis. When one-third of
the a-syn monomers are FKBP12-doped (/50.3), the final supra-
molecular aggregates are poorly branched (right lower panel). The
same morphology is observed experimentally in the ElteN378-
FKBP12 a-syn mixture. As above outlined, when />0.3, the kinetics
undergoes a drastic change, with the sample ending up in form-
ing few highly branched macro-aggregates (central lower panel).
In Supporting Information, we estimate that in the equimolar
FKBP12-a-syn solution the fraction a-syn monomers bearing a
bound FKBP12 is in the range /50.3:0.4. The estimate is based on
the measure of the fluorescence quenching of the strong trypto-
phan emission band at 300–350 nm occurring in FKBP12 solutions
upon ligand addition. The presence of the tight-binding inhibitor
ElteN378 in FKBP12-a-syn mixture lowers this fraction below 0.3,
corresponding to the value for the cross-over regime reported in
the inset of Figure 3).
Conclusions
We have shown using ThT fluorescence and microscopy, that
FKBP12 and a-syn in a 1:1 molar ratio spontaneously aggregate
forming a dendritic explosion of aggregated structures. This pro-
cess can be tamed, in a dose-dependent manner, using the non-
immunosuppressive ElteN378 synthetic inhibitor. CG simulations
showed that the aggregation of a-syn in linear fibrils as well as in
complex branched supramolecular aggregates is elicited by the
hydrophobic aggregation of the central non-polar NAC residues of
the monomeric unit. Remarkably, our rudimental CG model for
the a-syn monomer was able to reproduce the essential morpho-
logical features of the supramolecular aggregates in the final
stages with no necessity of introducing any detail on the second-
ary structure, therefore hinting that a continuous and variegate
b-reorganisation process follows the primary event of hydropho-
bic-driven association of the NAC domains in oligomers.
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